- Home
- IRWD
as of 03-26-2026 3:46pm EST
Ironwood Pharmaceuticals Inc is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities.
| Founded: | 1998 | Country: | United States |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | 741.8M | IPO Year: | 2009 |
| Target Price: | $4.94 | AVG Volume (30 days): | 2.9M |
| Analyst Decision: | Hold | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.15 | EPS Growth: | 1400.00 |
| 52 Week Low/High: | $0.55 - $5.78 | Next Earning Date: | 05-06-2026 |
| Revenue: | $298,276,000 | Revenue Growth: | 8.88% |
| Revenue Growth (this year): | 57.95% | Revenue Growth (next year): | 4.39% |
| P/E Ratio: | 21.27 | Index: | N/A |
| Free Cash Flow: | 127.0M | FCF Growth: | +22.82% |
AI-Powered IRWD Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Ironwood Pharmaceuticals Inc. (IRWD)
Chief Legal Officer
Avg Cost/Share
$3.66
Shares
19,053
Total Value
$69,733.98
Owned After
363,886
SEC Form 4
Chief Executive Officer
Avg Cost/Share
$3.66
Shares
103,526
Total Value
$378,905.16
Owned After
1,489,002
SEC Form 4
SVP, CMO, Head-Res&Drug
Avg Cost/Share
$3.66
Shares
17,012
Total Value
$62,263.92
Owned After
521,425
SEC Form 4
Principal Accounting Officer
Avg Cost/Share
$3.66
Shares
12,621
Total Value
$46,192.86
Owned After
252,636
SEC Form 4
Chief Financial Officer
Avg Cost/Share
$3.66
Shares
11,457
Total Value
$41,932.62
Owned After
160,601
SEC Form 4
Chief Commercial Officer
Avg Cost/Share
$3.66
Shares
11,239
Total Value
$41,134.74
Owned After
213,738
SEC Form 4
Chief Legal Officer
Avg Cost/Share
$3.81
Shares
17,439
Total Value
$66,442.59
Owned After
363,886
SEC Form 4
Chief Executive Officer
Avg Cost/Share
$3.81
Shares
94,757
Total Value
$361,024.17
Owned After
1,489,002
SEC Form 4
SVP, CMO, Head-Res&Drug
Avg Cost/Share
$3.81
Shares
15,570
Total Value
$59,321.70
Owned After
521,425
SEC Form 4
Principal Accounting Officer
Avg Cost/Share
$3.81
Shares
11,552
Total Value
$44,013.12
Owned After
252,636
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| John Minardo | IRWD | Chief Legal Officer | Feb 24, 2026 | Sell | $3.66 | 19,053 | $69,733.98 | 363,886 | |
| MCCOURT Thomas A | IRWD | Chief Executive Officer | Feb 24, 2026 | Sell | $3.66 | 103,526 | $378,905.16 | 1,489,002 | |
| Shetzline Michael | IRWD | SVP, CMO, Head-Res&Drug | Feb 24, 2026 | Sell | $3.66 | 17,012 | $62,263.92 | 521,425 | |
| Silver Ronald | IRWD | Principal Accounting Officer | Feb 24, 2026 | Sell | $3.66 | 12,621 | $46,192.86 | 252,636 | |
| Martini Gregory S. | IRWD | Chief Financial Officer | Feb 24, 2026 | Sell | $3.66 | 11,457 | $41,932.62 | 160,601 | |
| Gaskins Tammi L | IRWD | Chief Commercial Officer | Feb 24, 2026 | Sell | $3.66 | 11,239 | $41,134.74 | 213,738 | |
| John Minardo | IRWD | Chief Legal Officer | Feb 23, 2026 | Sell | $3.81 | 17,439 | $66,442.59 | 363,886 | |
| MCCOURT Thomas A | IRWD | Chief Executive Officer | Feb 23, 2026 | Sell | $3.81 | 94,757 | $361,024.17 | 1,489,002 | |
| Shetzline Michael | IRWD | SVP, CMO, Head-Res&Drug | Feb 23, 2026 | Sell | $3.81 | 15,570 | $59,321.70 | 521,425 | |
| Silver Ronald | IRWD | Principal Accounting Officer | Feb 23, 2026 | Sell | $3.81 | 11,552 | $44,013.12 | 252,636 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q4 Q4 2025 Earnings
8-K BUY Feb 25, 2026 · 63% conf.
Q4 2025 Earnings
8-K BUYFeb 25, 2026 · 63% conf.
1D
+3.73%
$3.49
Act: +8.93%
5D
+5.66%
$3.55
Act: +11.31%
20D
+2.14%
$3.43
false 0001446847
0001446847
2026-02-25 2026-02-25
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report Pursuant to
Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
February 25, 2026
IRONWOOD
PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Delaware
001-34620
04-3404176
(State or other jurisdiction
(Commission File Number)
(I.R.S.
Employer
of incorporation)
Identification Number)
100 Summer Street, Suite 2300
Boston, Massachusetts
02110
(Address of principal
(Zip code)
executive offices)
(617) 621-7722
(Registrant’s telephone number,
including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which
registered
Class A common stock, $0.001 par value
IRWD
Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 2.02 Results of Operations and Financial Condition.
On February 25, 2026, Ironwood Pharmaceuticals, Inc. issued a press release containing an update on its recent business activities as well as those for the quarter and year ended December 31, 2025. A copy of the press release is furnished as Exhibit 99.1 and is incorporated herein by reference.
The press release is being furnished pursuant to Item 2.02 of this Current Report on Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall such document be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No.
Description
99.1
Ironwood Pharmaceuticals, Inc. Press Release dated February 25, 2026
104
The cover page from this Current Report on Form 8-K, formatted in Inline XBRL
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Ironwood Pharmaceuticals, Inc.
Dated: February 25, 2026 By: /s/ Gregory Martini
Name: Gregory Martini
Title: Senior Vice President, Chief Financial Officer
2025 Q4 Q4 2025 Earnings
8-K BUY Jan 2, 2026 · 63% conf.
Q4 2025 Earnings
8-K BUYJan 2, 2026 · 63% conf.
1D
+3.73%
$3.49
Act: +8.93%
5D
+5.66%
$3.55
Act: +11.31%
20D
+2.14%
$3.43
false 0001446847
0001446847
2026-01-02 2026-01-02
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report Pursuant to
Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
January 2, 2026
IRONWOOD
PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Delaware
001-34620
04-3404176
(State or other jurisdiction
(I.R.S.
Employer
of incorporation)
(Commission File Number) Identification Number)
100 Summer Street, Suite 2300
Boston, Massachusetts
02110
(Address of principal
executive offices)
(Zip code)
(617) 621-7722
(Registrant’s telephone number,
including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which
registered
Class A common stock, $0.001 par value
IRWD
Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 2.02 Results of Operations and Financial Condition.
On January 2, 2026, Ironwood Pharmaceuticals, Inc. (the “Company”) issued a press release containing an update on its recent business activities. A copy of the press release is furnished as Exhibit 99.1 and is incorporated herein by reference.
The press release is being furnished pursuant to Item 2.02 of this Current Report on Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall such document be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No.
Description
99.1
Ironwood Pharmaceuticals, Inc. Press Release dated January 2, 2026
104
The cover page from this Current Report on Form 8-K, formatted in Inline XBRL
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Ironwood Pharmaceuticals, Inc.
Dated: January 2, 2026 By: /s/ Gregory Martini
Name: Gregory Martini
Title: Senior Vice President, Chief Financial Officer
2025 Q3 Q3 2025 Earnings
8-K Nov 10, 2025
Q3 2025 Earnings
8-KNov 10, 2025
false 0001446847
0001446847
2025-11-10 2025-11-10
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report Pursuant to
Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
November 10, 2025
IRONWOOD
PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Delaware
001-34620
04-3404176
(State or other jurisdiction
(I.R.S.
Employer
of incorporation)
(Commission File Number) Identification Number)
100 Summer Street, Suite 2300
Boston, Massachusetts
02110
(Address of principal
executive offices)
(Zip code)
(617) 621-7722
(Registrant’s telephone number,
including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which
registered
Class A common stock, $0.001 par value
IRWD
Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 2.02 Results of Operations and Financial Condition.
On November 10, 2025, Ironwood Pharmaceuticals, Inc. issued a press release containing an update on its recent business activities as well as those for the quarter ended September 30, 2025. A copy of the press release is furnished as Exhibit 99.1 and is incorporated herein by reference.
The press release is being furnished pursuant to Item 2.02 of this Current Report on Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall such document be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No.
Description
99.1
Ironwood Pharmaceuticals, Inc. Press Release dated November 10, 2025
104
The cover page from this Current Report on Form 8-K, formatted in Inline XBRL
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Ironwood Pharmaceuticals, Inc.
Dated: November 10, 2025 By: /s/ Gregory Martini
Name: Gregory Martini
Title: Senior Vice President, Chief Financial Officer
Compare IRWD vs Leading Stocks
See how IRWD stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "IRWD Ironwood Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.